AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Zhengye Biotechnology Holding Limited Class A Ordinary Shares
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI AK-0F9482A221
1.50▲ 0.04 (2.74%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
1.46
Day's Range
1.43 – 1.55
52-Week Range
0.62 – 8.01
Volume
83.7K
Avg Volume
857.4K
Share Statistics
Shares Outstanding
Employees
277
Exchange
XNAS
Listed
2025-01-07
Share count as of December 31, 2025

Zhengye Biotechnology Holding Limited Class A Ordinary Shares (ZYBT) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Zhengye Biotechnology Holding Limited Class A Ordinary Shares (ZYBT)
What is Zhengye Biotechnology Holding Limited Class A Ordinary Shares's Market Cap?
Zhengye Biotechnology Holding Limited Class A Ordinary Shares's Market Cap is $71.1M, based on as-reported figures from SEC (XBRL) filings.
What is Zhengye Biotechnology Holding Limited Class A Ordinary Shares's Enterprise Value?
Zhengye Biotechnology Holding Limited Class A Ordinary Shares's Enterprise Value is $65.0M, based on as-reported figures from SEC (XBRL) filings.
What is Zhengye Biotechnology Holding Limited Class A Ordinary Shares's Price / Sales?
Zhengye Biotechnology Holding Limited Class A Ordinary Shares's Price / Sales is 4.3×, based on as-reported figures from SEC (XBRL) filings.
What is Zhengye Biotechnology Holding Limited Class A Ordinary Shares's EV / Revenue?
Zhengye Biotechnology Holding Limited Class A Ordinary Shares's EV / Revenue is 3.9×, based on as-reported figures from SEC (XBRL) filings.
What is Zhengye Biotechnology Holding Limited Class A Ordinary Shares's EV / EBITDA?
Zhengye Biotechnology Holding Limited Class A Ordinary Shares's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Zhengye Biotechnology Holding Limited Class A Ordinary Shares's Revenue (TTM)?
Zhengye Biotechnology Holding Limited Class A Ordinary Shares's Revenue (TTM) is $16.6M, based on as-reported figures from SEC (XBRL) filings.
What is Zhengye Biotechnology Holding Limited Class A Ordinary Shares's Net Income (TTM)?
Zhengye Biotechnology Holding Limited Class A Ordinary Shares's Net Income (TTM) is -$10.0M, based on as-reported figures from SEC (XBRL) filings.
What is Zhengye Biotechnology Holding Limited Class A Ordinary Shares's EBITDA?
Zhengye Biotechnology Holding Limited Class A Ordinary Shares's EBITDA is -$6.4M, based on as-reported figures from SEC (XBRL) filings.
What is Zhengye Biotechnology Holding Limited Class A Ordinary Shares's Diluted EPS (TTM)?
Zhengye Biotechnology Holding Limited Class A Ordinary Shares's Diluted EPS (TTM) is -0.21, based on as-reported figures from SEC (XBRL) filings.
What is Zhengye Biotechnology Holding Limited Class A Ordinary Shares's EBITDA Margin?
Zhengye Biotechnology Holding Limited Class A Ordinary Shares's EBITDA Margin is -38.3%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · ZYBTAs-filed SEC (XBRL) data
No Quarterly data available for this company — showing Annual instead. This company files annual reports only — foreign private issuers (Form 20-F / 40-F) are not required to file quarterly reports, so no quarterly figures exist to show.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of CNY, except per-share data)
Source: Akyla.ai
Line ItemDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022
Net revenues
YoY growth-37.6%
Cost of revenues
Gross profit
% of revenue20.5%
Sales and marketing expenses
General and administrative expenses
Research and development expenses
Reversal of (provision for) credit losses
Total operating expenses
% of revenue-81.1%
Operating income (loss)
% of revenue-60.6%
Other income (expenses):
Interest income
Interest expense
Unrealized gains on short-term investments
Unrealized foreign exchange gain (loss)
Government subsidy
Other expenses (income)
Total other expenses, net
Income (loss) before income taxes
Income tax expenses
Net income (loss)
% of revenue-71.3%
Net (income) loss attributable to noncontrolling interests
Net income (loss) attributable to the Zhengye Biotechnology Holding Limited’s shareholders
% of revenue-60.0%
Net income (loss)
% of revenue-71.3%
Net (income) loss attributable to noncontrolling interests
Total comprehensive (income) loss attributable to non-controlling interest
Total comprehensive income (loss) attributable to the Zhengye Biotechnology Holding Limited’s shareholders
Basic – ordinary shares (in Dollars per share and Yuan Renminbi per share)—
Diluted – ordinary shares (in Dollars per share and Yuan Renminbi per share)—